Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 36,558

Document Document Title
WO/2018/127801A1
Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infect...  
WO/2018/126523A1
The invention provides a synthesis method of a proline-histidine cyclodipeptide, comprising: preparing an amino-protected proline-histidine dipeptide methyl ester from histidine and proline, wherein one of histidine and valine is a methy...  
WO/2018/129411A1
Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases o...  
WO/2018/127184A1
The present invention relates to a compound of formula (I) and a pharmaceutical composition and preparation method thereof. The compound can be used as an ALK inhibitor for treating an ALK-mediated disease. The present invention also rel...  
WO/2018/129405A1
Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) and their use for treating neurodegenerative diseases, such as, neurodegenerative diseases associated with high levels of ceramide, including, but not limited to Alzheimer...  
WO/2018/127195A1
The present invention provides a substituted fused heteroaryl compound serving as a kinase inhibitor, and applications thereof. Specifically, the present invention provides a compound represented by formula I, or a medicinal salt or a pr...  
WO/2018/127465A1
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.  
WO/2018/129387A1
Compositions, combinations and methods comprising the administration of a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of abnormal cellular pr...  
WO/2018/125961A1
The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method o...  
WO/2018/121650A1
Disclosed are an FGFR inhibitor and the use thereof in the preparation of a drug for treating FGFR-related diseases. In particular, disclosed are a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.  
WO/2018/125746A1
The present invention relates to 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the d...  
WO/2018/122724A1
The present invention relates to improved process for the preparation of Temozolomide Formula I. Said Temozolomide (I) is useful in the treatment of cancer.  
WO/2018/124001A1
The present invention pertains to novel, exceptional low-molecular compounds that specifically antagonize the BMP signaling pathway, and because these compounds can be used to modulate cell growth, differentiation, proliferation, and apo...  
WO/2018/124060A1
Provided is a compound represented by general formula (1) or a pharmaceutically-acceptable salt thereof. [In formula (1), R1 and R2 may be the same or different from each other, and each represents a hydrogen atom, a halogen atom, a hydr...  
WO/2018/122212A1
Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.  
WO/2018/121754A1
A light emitting device, comprising: a light emitting element and a light conversion portion; the light conversion portion absorbs primary light emitted from the light emitting element and converts the same into secondary light having a ...  
WO/2018/121228A1
The present invention relates to a compound having AXL inhibitory activities, a preparation method therefor and use thereof. In particular, disclosed is a compound of a structure as represented by formula (I), each group and substituent ...  
WO/2018/122550A1
A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: • B is an aryl or heteroaryl group optionally substituted by one or more R10 groups; and * X is sele...  
WO/2018/126140A1
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof,...  
WO/2018/123467A1
An indoloquinazoline compound represented by a specific structure. Clones having exceptional AI activity were detected by metagenomic analysis, and a novel indoloquinazoline compound synthase was identified from the clones. The novel ind...  
WO/2018/124236A1
Provided is a medicinal composition to be used for treating an intractable heart tissue fibrosis disease accompanying chronic heart failure. The medicinal composition, which is to be used for treating an intractable heart tissue fibrosis...  
WO/2018/125810A1
A chemical entity of Formula (I), wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities, methods of making them; and their use in a wide range of methods, including metabolic ...  
WO/2018/124313A1
A compound of formula (I), a material for an organic electroluminescence device comprising at least one compound of formula (I); an organic electroluminescence device which comprises an organic thin film layer between a cathode and an an...  
WO/2018/126143A1
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof,...  
WO/2018/123783A1
Provided are a practically useful organic EL element which has high efficiency and high drive stability, and a compound suitable for the organic EL element. The present invention pertains to a compound that is for an organic electrolumin...  
WO/2018/119441A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of receptor tyrosine kinase (RTK) proteins. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end ...  
WO/2018/118791A2
Novel quinazolinones useful as inhibitors of tau oligomer formation, useful for the treatment of neurodegenerative diseases and related conditions are disclosed. The invention also relates to the pharmaceutically acceptable salts of said...  
WO/2018/113085A1
The present invention relates to a compound of formula I and pharmaceutically acceptable salts, solvates, active metabolites, polycrystalline compounds, esters, isomers or prodrugs thereof, a pharmaceutical composition containing the com...  
WO/2018/118891A1
Described herein are methods and intermediates useful for making substituted porphyrins, including Mn(III) ortho N-butoxyethylpyridylporphyrin, and compositions comprising the same. In some embodiments, a method of the present invention ...  
WO/2018/112589A1
The present invention relates to an efficient and industrially advantageous process for preparing temozolomide and the carbamoyl-AICA intermediate through the use of N-methyl carbamoylimidazole in a good overall yield and high purity.  
WO/2018/118109A1
Disclosed is a composition which is BA-1049 (R).  
WO/2018/119208A1
The present disclosure provides certain angular tricyclic compounds that are histone methyltransi erases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as c...  
WO/2018/113624A1
The invention discloses a type of fused imidazole compound, preparation method and application thereof. The structure of the compound is shown in general formula I. The definition of each group therein is as described in the specificatio...  
WO/2018/114663A1
The invention relates to substituted azolylpyrrolones and azolylhydantoines of general formula (I) and salts thereof, wherein the groups of general formula (I) are defined as cited in the description, and to the use thereof as herbicides...  
WO/2018/119266A1
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...  
WO/2018/117153A1
The present invention relates to crystalline forms of the Janus kinase (JAK) inhibitor 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6- diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A), as well as, compositions the...  
WO/2018/114677A2
The present invention covers [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1H-1,2,3-tria zol-5-yl)methanone compounds of general formula (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, ...  
WO/2018/113771A1
The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant r...  
WO/2018/116872A1
[Problem] To provide: a novel glycoluril or the like; and a method for producing the glycoluril or the like. [Solution] A nitrogen-containing cyclic compound which is represented by formula (1); and the nitrogen-containing cyclic compoun...  
WO/2018/119036A1
Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R1, R2, R3, R4, R5, R6, ...  
WO/2018/115822A1
This invention relates to cucurbituril and/or one or more derivatives thereof with low formaldehyde content, to a process of manufacturing said cucurbituril and/or one or more derivatives thereof and to the use of said cucurbituril and/o...  
WO/2018/113538A1
The present invention relates to an organic compound with homobenzene as a core and the use thereof in an OLED device. The compound of the present invention has a higher glass transition temperature, a higher molecular heat stability, ap...  
WO/2018/119325A1
Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, also disclosed herein include methods of activating and enhancing the cGAS-STING response and use of an im...  
WO/2018/119362A2
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).  
WO/2018/119263A1
Disclosed are compounds of Formula (I'), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing o...  
WO/2018/115965A1
In some embodiments, the invention relates to crystalline solid forms, including polymorphs and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5 - a]pyrazin-1-yl)-2-methoxy-N-(pyridin-2-yl)benzamide. In some em...  
WO/2018/112840A1
6, 5-fused heteroarylpiperidine ether compounds and pharmaceutical compositions thereof are disclosed. The 6, 5-fused heteroarylpiperidine ether compounds are allosteric modulators of the M4 muscarinic acetylcholine receptor and can be u...  
WO/2018/115380A1
The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this...  
WO/2018/118842A1
The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) via inhibition of...  
WO/2018/117406A1
The present invention relates to an azepine derivative acting on a 5-HT7 receptor, and a pharmaceutically acceptable salt thereof. The present invention has excellent binding affinity and excellent antagonistic activity with respect to a...  

Matches 1 - 50 out of 36,558